-+ 0.00%
-+ 0.00%
-+ 0.00%
Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
Share
Listen to the news

Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).

Evaluating sacituzumab tirumotecan (sac-TMT), the trial marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior lines of systemic therapy.

sac-TMT is an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech.

Trial Efficacy And Safety Results

At final analysis, sac-TMT delivered a statistically significant and clinically meaningful OS improvement compared to treatment of physician’s choice (TPC), which consisted of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.

Researchers observed generally consistent results across patient subgroups regardless of TROP2 expression status.

However, sac-TMT did not meet its secondary endpoint of progression-free survival (PFS).

Although the therapy demonstrated a nominally improved benefit in objective response rate (ORR) favoring sac-TMT over TPC, investigators did not formally test this secondary endpoint under the prespecified analysis plan.

The therapy maintained a safety profile consistent with previously reported sac-TMT studies, revealing no new safety signals.

Expanding TroFuse Clinical Program

TroFuse-015 marks the second positive Phase 3 study from Merck’s global TroFuse clinical development program for sac-TMT.

The program currently comprises 18 ongoing global Phase 3 trials across multiple tumor types, representing the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date.

Merck is evaluating sac-TMT as both a monotherapy and in combination with immunotherapies spanning early-to-late-stage disease.

The studies cover endometrial, bladder, breast, cervical, gastric, non-small cell lung, and ovarian cancers, with 14 of the 18 Phase 3 studies—including TroFuse-015.

MRK Price Action: Merck & Co shares were up 2.07% at $135.56 at the time of publication on Friday, according to Benzinga Pro data.

Image via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending